MBX Biosciences, Inc. (MBX)
NASDAQ: MBX · Real-Time Price · USD
20.36
+0.09 (0.44%)
Dec 20, 2024, 4:00 PM EST - Market closed
MBX Biosciences Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| TTM
| FY 2023 | FY 2022 |
| Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
| Selling, General & Admin | 9.86 | 6.98 | 3.86 |
| Research & Development | 49.72 | 28.33 | 21.3 |
| Operating Expenses | 59.58 | 35.31 | 25.16 |
| Operating Income | -59.58 | -35.31 | -25.16 |
| Interest Expense | - | - | -0.37 |
| Interest & Investment Income | 3.35 | 1.7 | 0.35 |
| Other Non Operating Income (Expenses) | - | - | -0.07 |
| EBT Excluding Unusual Items | -56.22 | -33.61 | -25.26 |
| Gain (Loss) on Sale of Investments | 1.04 | 1.04 | 0.03 |
| Other Unusual Items | - | - | -0.9 |
| Pretax Income | -55.18 | -32.56 | -26.14 |
| Net Income | -55.18 | -32.56 | -26.14 |
| Net Income to Common | -55.18 | -32.56 | -26.14 |
| Shares Outstanding (Basic) | 14 | 12 | 8 |
| Shares Outstanding (Diluted) | 14 | 12 | 8 |
| Shares Change (YoY) | 71.70% | 52.73% | - |
| EPS (Basic) | -4.01 | -2.66 | -3.26 |
| EPS (Diluted) | -4.01 | -2.66 | -3.26 |
| Free Cash Flow | -50.63 | -32.11 | -23.56 |
| Free Cash Flow Per Share | -3.68 | -2.62 | -2.94 |
| EBITDA | -59.35 | -35.15 | -25.11 |
| D&A For EBITDA | 0.23 | 0.16 | 0.06 |
| EBIT | -59.58 | -35.31 | -25.16 |
Source: S&P Capital IQ. Standard template.
Financial Sources.